UNBS5162 and Amonafide Inhibits Tumor Progression in Human Melanoma by the AKT/mTOR Pathway

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Apr 10

PMID 30962721

Citations 6

Authors

Yingyi Ye

Shuhong Huang

Yingying Wu

Affiliations

Soon will be listed here.

Abstract

Background: Human melanoma is a malignant tumor originated from melanocytes with high invasion, metastasis, and poor prognosis. In this study, the effects of naphthalimides UNBS5162 and amonafide on the properties of proliferation and apoptosis in human melanoma cells were confirmed.

Methods: Cell proliferation was determined by CCK8 and clone formation assay. Transwell assay was performed to detect the migration and invasion of M14 and A375 cells. Cell apoptosis was estimated using flow cytometry.

Results: In a drug sensitivity assay, cell viability decreased with increasing concentrations of UNBS5162 or amonafide. Likewise, proliferation of M14 or A375 cells treated with 10 μM UNBS5162 or 8 μM amonafide decreased significantly when compared with negative control (NC) cells, their inhibition effect verified by means of a clone formation assay. After the treatment with UNBS5162 or amonafide, the migration of melanoma cells was inhibited in a dosede-pendent manner. The number of invaded cells treated with UNBS5162 was also significantly reduced when compared with those of the NC cells. The apoptotic cell numbers treated with UNBS5162 or amonafide decreased significantly when compared with the M14 and A375 cells in the NC group. According to Western blot results, phosphorylation of AKT and expressions of mesenchymal marker factors were inhibited in cells treated with UNBS5162 or amonafide.

Conclusion: These results reveal that UNBS5162 inhibits the cell activity of melanoma cells through the AKT/mTOR signaling pathway, and reverses epithelial-mesenchymal transition conversion in human melanoma cells. This study on UNBS5162 and amonafide in melanomas provides an experimental basis of their uses and potential value on human melanoma treatment.

Citing Articles

Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects.

Hajjo R, Sabbah D, Tropsha A Pathogens. 2022; 11(7).

PMID: 35889989 PMC: 9320269. DOI: 10.3390/pathogens11070743.

Knockdown of long noncoding RNA HUMT inhibits the proliferation and metastasis by regulating miR-455-5p/LRP4 axis in hepatocellular carcinoma.

Zou X, Sun P, Xie H, Fan L, Ding K, Wang J Bioengineered. 2022; 13(4):8051-8063.

PMID: 35293286 PMC: 9162019. DOI: 10.1080/21655979.2022.2051841.

Downregulation of sperm-associated antigen 5 inhibits melanoma progression by regulating forkhead box protein M1/A disintegrin and metalloproteinase 17/NOTCH1 signaling.

Dang L, Shi C, Zhang Q, Liao P, Wang Y Bioengineered. 2022; 13(3):4744-4756.

PMID: 35138218 PMC: 8974132. DOI: 10.1080/21655979.2022.2031670.

PSMC2/ITGA6 axis plays critical role in the development and progression of hepatocellular carcinoma.

Duan X, Li H, Wang M, Ju S, Li F, Chen P Cell Death Discov. 2021; 7(1):217.

PMID: 34413286 PMC: 8376978. DOI: 10.1038/s41420-021-00585-y.

High expression of PSMC2 promotes gallbladder cancer through regulation of GNG4 and predicts poor prognosis.

Zhu D, Gu X, Lin Z, Yu D, Wang J Oncogenesis. 2021; 10(5):43.

PMID: 34016944 PMC: 8138011. DOI: 10.1038/s41389-021-00330-1.

References

Schrader A, Lechner O, Templin M, Dittmar K, Machtens S, Mengel M . CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer. 2002; 86(8):1250-6. PMC: 2375348. DOI: 10.1038/sj.bjc.6600221. View

Dhawan P, Richmond A . Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol. 2002; 72(1):9-18. PMC: 2668262. View

Lens M, Dawes M . Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004; 150(2):179-85. DOI: 10.1111/j.1365-2133.2004.05708.x. View

Jordan J, Sun W, Hussain S, DeAngulo G, Prabhu S, Heimberger A . Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2007; 57(1):123-31. PMC: 11030978. DOI: 10.1007/s00262-007-0336-x. View

Viola A, Luster A . Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol. 2007; 48:171-97. DOI: 10.1146/annurev.pharmtox.48.121806.154841. View

Soria G, Ben-Baruch A . The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008; 267(2):271-85. DOI: 10.1016/j.canlet.2008.03.018. View

Mijatovic T, Mahieu T, Bruyere C, De Neve N, Dewelle J, Simon G . UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia. 2008; 10(6):573-86. PMC: 2386542. DOI: 10.1593/neo.08290. View

Singh S, Sadanandam A, Varney M, Nannuru K, Singh R . Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion. Int J Cancer. 2009; 126(2):328-36. PMC: 2794956. DOI: 10.1002/ijc.24714. View

Garbe C, Eigentler T, Keilholz U, Hauschild A, Kirkwood J . Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011; 16(1):5-24. PMC: 3228046. DOI: 10.1634/theoncologist.2010-0190. View

10.

Li X, Lin Y, Wang Q, Yuan Y, Zhang H, Qian X . The novel anti-tumor agents of 4-triazol-1,8-naphthalimides: synthesis, cytotoxicity, DNA intercalation and photocleavage. Eur J Med Chem. 2011; 46(4):1274-9. DOI: 10.1016/j.ejmech.2011.01.050. View

11.

Verbeke H, Hannelien V, Geboes K, Karel G, Van Damme J, Jo V . The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta. 2011; 1825(1):117-29. DOI: 10.1016/j.bbcan.2011.10.008. View

12.

Seregard S, Singh A . Retinoblastoma: direct chemotherapeutic drug delivery into the vitreous cavity. Br J Ophthalmol. 2012; 96(4):473-4. DOI: 10.1136/bjophthalmol-2012-301528. View

13.

Lira S, Furtado G . The biology of chemokines and their receptors. Immunol Res. 2012; 54(1-3):111-20. PMC: 4115270. DOI: 10.1007/s12026-012-8313-7. View

14.

Jazirehi A, Wenn P, Damavand M . Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy. Am J Cancer Res. 2012; 2(2):178-91. PMC: 3304564. View

15.

Mahadevan D, Northfelt D, Chalasani P, Rensvold D, Kurtin S, Von Hoff D . Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. Int J Clin Oncol. 2012; 18(5):934-41. PMC: 6075731. DOI: 10.1007/s10147-012-0475-8. View

16.

Wu S, Singh S, Varney M, Kindle S, Singh R . Modulation of CXCL-8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasis. Cancer Med. 2013; 1(3):306-17. PMC: 3544458. DOI: 10.1002/cam4.28. View

17.

OBoyle G, Swidenbank I, Marshall H, Barker C, Armstrong J, White S . Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070. Br J Cancer. 2013; 108(8):1634-40. PMC: 3668477. DOI: 10.1038/bjc.2013.124. View

18.

Stone R, Mazzola E, Neuberg D, Allen S, Pigneux A, Stuart R . Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015; 33(11):1252-7. DOI: 10.1200/JCO.2014.57.0952. View

19.

Michielin O, Hoeller C . Gaining momentum: New options and opportunities for the treatment of advanced melanoma. Cancer Treat Rev. 2015; 41(8):660-70. DOI: 10.1016/j.ctrv.2015.05.012. View

20.

Kobayashi H, Nobeyama Y, Nakagawa H . Tumor-suppressive effects of natural-type interferon-β through CXCL10 in melanoma. Biochem Biophys Res Commun. 2015; 464(2):416-21. DOI: 10.1016/j.bbrc.2015.06.122. View